Skip to Main Content

Paper Details

Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non-Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO<sub>2</sub>TECT Randomized Clinical Trial of ESA-Naïve Patients.
Kidney Med
2
2023
CKD, Darbepoetin Alfa, NDD, NDD-CKD, Non-Dialysis-Dependent CKD, Patients, Vadadustat, anemia, chronic kidney disease, darbepoetin alfa, heart failure, hypoxia-inducible factor prolyl hydroxylase, kidney failure, kidney-related deaths, non, nonfatal myocardial infarction, patients, prolyl, stroke, thromboembolic event, vadadustat, vascular access thrombosis
Author NameAffiliation
Kai-Uwe EckardtCharite-Universitatsmedizin Berlin
Peter A McCulloughTruth for Health Foundation
  • 1 - 2

Datasets

Release 1.2